Relation of Copeptin with Diabetic and Renal Function Markers Among Patients with Diabetes Mellitus Progressing Towards Diabetic Nephropathy.


Journal

Archives of medical research
ISSN: 1873-5487
Titre abrégé: Arch Med Res
Pays: United States
ID NLM: 9312706

Informations de publication

Date de publication:
08 2020
Historique:
received: 10 03 2020
revised: 10 05 2020
accepted: 21 05 2020
pubmed: 9 6 2020
medline: 18 11 2020
entrez: 8 6 2020
Statut: ppublish

Résumé

Arginine vasopressin (AVP) plays an important role in the pathophysiology of Diabetes Mellitus (DM) and its related complications like diabetic nephropathy. Copeptin is considered as a reliable surrogate biomarker of AVP. If raised levels of copeptin in diabetic patients are detected earlier, prognosis of DM can be improved by timely modulating the treatment strategy. The study is therefore planned to assess copeptin levels in different groups of DM and in healthy controls to suggest a better and reliable biomarker for progressive stages of DM. Subjects were recruited as controls, pre diabetes, DM without nephropathy and diabetic nephropathy. Serum copeptin levels were measured by ELISA. While, Blood Urea Nitrogen (BUN), creatinine, Glycosylated Hemoglobin (HbA1c) and spot urinary albumin creatinine ratio (UACR) were done using spectrophotometry. Statistical analysis was done using ANOVA and Pearson's correlation tests on SPSS. The average copeptin levels were 215.096 pg/mL. Copeptin levels were significantly elevated in subjects with positive family history of DM (p = 0.025), levels were also raised in pre diabetes kpatients (252.85 pg/mL) as compared to other groups. Copeptin levels were also correlated with HbA1c r = 0.171 (p = 0.101), BUN r = 0.244 (p = 0.007), creatinine r = 0.215 (p = 0.018), UACR r = 0.375 (p = <0.001) and GFR r = 0.215 (p = <0.019). The significant correlation of copeptin with diabetic and renal biomarkers, along with its positive association with family history of DM support its' role as an early and reliable biomarker of DM and its associated nephropathy.

Sections du résumé

BACKGROUND
Arginine vasopressin (AVP) plays an important role in the pathophysiology of Diabetes Mellitus (DM) and its related complications like diabetic nephropathy. Copeptin is considered as a reliable surrogate biomarker of AVP. If raised levels of copeptin in diabetic patients are detected earlier, prognosis of DM can be improved by timely modulating the treatment strategy.
AIMS OF THE STUDY
The study is therefore planned to assess copeptin levels in different groups of DM and in healthy controls to suggest a better and reliable biomarker for progressive stages of DM.
METHODS
Subjects were recruited as controls, pre diabetes, DM without nephropathy and diabetic nephropathy. Serum copeptin levels were measured by ELISA. While, Blood Urea Nitrogen (BUN), creatinine, Glycosylated Hemoglobin (HbA1c) and spot urinary albumin creatinine ratio (UACR) were done using spectrophotometry. Statistical analysis was done using ANOVA and Pearson's correlation tests on SPSS.
RESULTS
The average copeptin levels were 215.096 pg/mL. Copeptin levels were significantly elevated in subjects with positive family history of DM (p = 0.025), levels were also raised in pre diabetes kpatients (252.85 pg/mL) as compared to other groups. Copeptin levels were also correlated with HbA1c r = 0.171 (p = 0.101), BUN r = 0.244 (p = 0.007), creatinine r = 0.215 (p = 0.018), UACR r = 0.375 (p = <0.001) and GFR r = 0.215 (p = <0.019).
CONCLUSION
The significant correlation of copeptin with diabetic and renal biomarkers, along with its positive association with family history of DM support its' role as an early and reliable biomarker of DM and its associated nephropathy.

Identifiants

pubmed: 32505416
pii: S0188-4409(20)30306-4
doi: 10.1016/j.arcmed.2020.05.018
pii:
doi:

Substances chimiques

AVP protein, human 0
Biomarkers 0
Glycopeptides 0
Neurophysins 0
Protein Precursors 0
copeptins 0
Vasopressins 11000-17-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

548-555

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 IMSS. Published by Elsevier Inc. All rights reserved.

Auteurs

Tooba Noor (T)

Department of Physiology, Dow University of Health Sciences, OJHA Campus, SUPARCO Road, Karachi, Pakistan.

Farina Hanif (F)

Institute of Biomedical Sciences, Dow University of Health Sciences, OJHA Campus, SUPARCO Road, Karachi, Pakistan. Electronic address: farina.hanif@duhs.edu.pk.

Zareen Kiran (Z)

National Institute of Diabetes and Endocrinology, Dow University of Health Sciences, OJHA Campus, SUPARCO Road, Karachi, Pakistan.

Rehana Rehman (R)

Department of Biological and Biomedical Sciences, Aga Khan University, Stadium Road, Karachi, Pakistan.

Muhammad Tassaduq Khan (MT)

Department of Nephrology, Dow University of Health Sciences, OJHA Campus, SUPARCO Road, Karachi, Pakistan.

Zeba Haque (Z)

Institute of Biomedical Sciences, Dow University of Health Sciences, OJHA Campus, SUPARCO Road, Karachi, Pakistan.

Kelash Nankani (K)

Department of Physiology, Dow University of Health Sciences, OJHA Campus, SUPARCO Road, Karachi, Pakistan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH